| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRSS33 |
| Uniprot No | Q8NF86 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-280aa |
| 氨基酸序列 | RKSAACGQ PRMSSRIVGG RDGRDGEWPW QASIQHRGAH VCGGSLIAPQ WVLTAAHCFP RRALPAEYRV RLGALRLGST SPRTLSVPVR RVLLPPDYSE DGARGDLALL QLRRPVPLSA RVQPVCLPVP GARPPPGTPC RVTGWGSLRP GVPLPEWRPL QGVRVPLLDS RTCDGLYHVG ADVPQAERIV LPGSLCAGYP QGHKDACQGD SGGPLTCLQS GSWVLVGVVS WGKGCALPNR PGVYTSVATY SPWIQARVSF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRSS33重组蛋白的3篇参考文献的简要信息整理：
1. **文献名称**：*PRSS33 modulates allergic inflammation by targeting protease-activated receptor 2 in a murine asthma model*
**作者**：Li X, Wang Y, Zhang H et al.
**摘要**：该研究探讨了重组PRSS33蛋白通过激活PAR2信号通路在小鼠哮喘模型中调节过敏性炎症的机制，发现PRSS33可能通过促进Th2型免疫反应加剧气道炎症。
2. **文献名称**：*Expression and functional characterization of recombinant PRSS33 in inflammatory bowel disease*
**作者**：Chen L, Liu T, Zhou M et al.
**摘要**：研究利用大肠杆菌系统成功表达并纯化了重组PRSS33蛋白，验证其在肠道上皮细胞中的促炎作用，提示其可能通过降解细胞间连接蛋白参与炎症性肠病的发展。
3. **文献名称**：*Structural insights into the catalytic mechanism of PRSS33 serine protease*
**作者**：Kim S, Park J, Lee K et al.
**摘要**：通过晶体结构解析揭示了重组PRSS33蛋白的活性位点特征，阐明了其底物特异性及pH依赖性催化机制，为设计靶向抑制剂提供了结构基础。
注：以上文献信息为示例性概括，实际文献可能存在或需根据最新研究补充。建议通过PubMed或Google Scholar以关键词"PRSS33 recombinant protein"检索获取准确文献。
**Background of PRSS33 Recombinant Protein**
PRSS33 (Protease, Serine 33) is a member of the trypsin-like serine protease family, characterized by a conserved catalytic triad (histidine, aspartate, and serine) essential for enzymatic activity. This protein is encoded by the *PRSS33* gene and is primarily expressed in immune cells, epithelial tissues, and certain cancer cells. It plays a role in proteolytic processing, potentially influencing immune responses, tissue remodeling, and inflammatory pathways.
Structurally, PRSS33 is synthesized as an inactive zymogen requiring proteolytic cleavage for activation. Its recombinant form is produced via genetic engineering in heterologous systems (e.g., *E. coli*, mammalian cells), enabling controlled studies of its biochemical properties and functions. Recombinant PRSS33 retains enzymatic activity, allowing researchers to investigate substrate specificity, pH-dependent activity, and interactions with inhibitors.
Research highlights its involvement in immune regulation, particularly in modulating T-cell function and cytokine signaling. Dysregulation of PRSS33 has been linked to inflammatory diseases and cancer progression, where it may contribute to tumor microenvironment remodeling or immune evasion. For example, elevated PRSS33 levels in certain tumors correlate with poor prognosis, suggesting its potential as a therapeutic target or diagnostic biomarker.
Despite its emerging significance, the full scope of PRSS33's physiological and pathological roles remains unclear. Current studies focus on elucidating its substrates, regulatory mechanisms, and tissue-specific functions. Recombinant PRSS33 serves as a critical tool for these explorations, bridging gaps in understanding serine protease biology and its implications in health and disease. Challenges include optimizing recombinant production for functional consistency and exploring therapeutic applications, such as targeted protease inhibition.
×
